Pharmaceutical

IRLAB Publishes Interim Eeport for the Period January-March 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / May 8, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 8, 2024 - IRLAB Therapeutics…

5 months ago

Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives

GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical…

5 months ago

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that…

5 months ago

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 [1] Enrollment…

5 months ago

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest

Curia & Carterra Biologics Symposium Biologics symposium slated for May 31 in Seattle, WA ALBANY, N.Y. and SALT LAKE CITY,…

5 months ago

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the…

5 months ago

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide)…

5 months ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Pre-treatment Sample of Patient’s Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with…

5 months ago

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

5 months ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton…

5 months ago